Alain Veilleux1,2,3, Vincenzo Di Marzo1,2,3,4,5, Cristoforo Silvestri6,7,8. 1. École de nutrition, Université Laval, Québec, QC, Canada. 2. Institut sur la nutrition et les aliments fonctionnels, Université Laval, Québec, QC, Canada. 3. Canadian Excellence Research Chair on the Microbiome-Endocannabinoidome Axis in Metabolic Health, Québec, Canada. 4. Institut de cardiologie et de pneumologie de Québec, Université Laval, Québec, QC, Canada. 5. Department de médecine, Université Laval, Québec, QC, Canada. 6. Canadian Excellence Research Chair on the Microbiome-Endocannabinoidome Axis in Metabolic Health, Québec, Canada. cristoforo.silvestri@criucpq.ulaval.ca. 7. Institut de cardiologie et de pneumologie de Québec, Université Laval, Québec, QC, Canada. cristoforo.silvestri@criucpq.ulaval.ca. 8. Department de médecine, Université Laval, Québec, QC, Canada. cristoforo.silvestri@criucpq.ulaval.ca.
Abstract
PURPOSE OF REVIEW: The endocannabinoid (eCB) system, i.e. the receptors that respond to the psychoactive component of cannabis, their endogenous ligands and the ligand metabolic enzymes, is part of a larger family of lipid signals termed the endocannabinoidome (eCBome). We summarize recent discoveries of the roles that the eCBome plays within peripheral tissues in diabetes, and how it is being targeted, in an effort to develop novel therapeutics for the treatment of this increasingly prevalent disease. RECENT FINDINGS: As with the eCB system, many eCBome members regulate several physiological processes, including energy intake and storage, glucose and lipid metabolism and pancreatic health, which contribute to the development of type 2 diabetes (T2D). Preclinical studies increasingly support the notion that targeting the eCBome may beneficially affect T2D. The eCBome is implicated in T2D at several levels and in a variety of tissues, making this complex lipid signaling system a potential source of many potential therapeutics for the treatments for T2D.
PURPOSE OF REVIEW: The endocannabinoid (eCB) system, i.e. the receptors that respond to the psychoactive component of cannabis, their endogenous ligands and the ligand metabolic enzymes, is part of a larger family of lipid signals termed the endocannabinoidome (eCBome). We summarize recent discoveries of the roles that the eCBome plays within peripheral tissues in diabetes, and how it is being targeted, in an effort to develop novel therapeutics for the treatment of this increasingly prevalent disease. RECENT FINDINGS: As with the eCB system, many eCBome members regulate several physiological processes, including energy intake and storage, glucose and lipid metabolism and pancreatic health, which contribute to the development of type 2 diabetes (T2D). Preclinical studies increasingly support the notion that targeting the eCBome may beneficially affect T2D. The eCBome is implicated in T2D at several levels and in a variety of tissues, making this complex lipid signaling system a potential source of many potential therapeutics for the treatments for T2D.
Authors: Jin Won Yang; Hyo Seon Kim; Ji Hye Im; Ji Won Kim; Dae Won Jun; Sung Chul Lim; Kyeong Lee; Jong Min Choi; Sang Kyum Kim; Keon Wook Kang Journal: FASEB J Date: 2015-09-23 Impact factor: 5.191
Authors: Douglas Osei-Hyiaman; Michael DePetrillo; Pál Pacher; Jie Liu; Svetlana Radaeva; Sándor Bátkai; Judith Harvey-White; Ken Mackie; László Offertáler; Lei Wang; George Kunos Journal: J Clin Invest Date: 2005-05 Impact factor: 14.808
Authors: Akhila Mallipedhi; Sarah L Prior; Gareth Dunseath; Richard M Bracken; Jonathan Barry; Scott Caplin; Nia Eyre; James Morgan; John N Baxter; Saoirse E O'Sullivan; Sarir Sarmad; David A Barrett; Stephen C Bain; Steve D Luzio; Jeffrey W Stephens Journal: J Diabetes Res Date: 2015-03-22 Impact factor: 4.011
Authors: Christopher Lipina; Sarah K Walsh; Sharon E Mitchell; John R Speakman; Cherry L Wainwright; Harinder S Hundal Journal: FASEB J Date: 2018-08-27 Impact factor: 5.191
Authors: Gerwyn Morris; Luba Sominsky; Kenneth R Walder; Michael Berk; Wolfgang Marx; André F Carvalho; Chiara C Bortolasci; Michael Maes; Basant K Puri Journal: Mol Neurobiol Date: 2022-03-26 Impact factor: 5.682